- Home
- WAFU vs INDP Comparison
WAFU vs INDP Comparison
Compare WAFU & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WAFU | INDP |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 4.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | WAFU | INDP |
|---|---|---|
| Price | $1.64 | $2.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.2K | ★ 44.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,186,645.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $1.65 |
| 52 Week High | $7.49 | $47.60 |
Technical Indicators
Market Signals| Indicator | WAFU | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 48.24 |
| Support Level | $1.60 | $2.39 |
| Resistance Level | $1.70 | $2.94 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 22.22 | 56.36 |
Price Performance
Historical ComparisonAbout WAFU Wah Fu Education Group Limited
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.